Abstract
The effects of L-DOPA (0, 25, and 50 mg/kg body weight) administration on peripheral pruritogen-induced scratching behavior and on brain monoamine and amino acid metabolism were investigated in mice. Intraperitoneal injection of L-DOPA significantly suppressed the number of scratches caused by subcutaneous injection of compound 48/80 (C48/80) in a dose-dependent manner. In the brain stem, C48/80 increased the norepinephrine turnover rate, but the change in the frequency of scratching was not paralleled by the changes in monoamine levels or by the monoamine turnover rates in the brain. On the other hand, most amino acids in the brain stem showed the highest levels in mice treated with C48/80 without L-DOPA, and these values were clearly decreased by L-DOPA administration. These changes in the concentrations of amino acids may be involved in the regulation of the frequency of scratching induced by L-DOPA. In particular, treatment with L-DOPA and C48/80 markedly decreased the concentrations of GABA, L-glutamine, Lglutamic acid, and glycine in the brain stem. In conclusion, L-DOPA administration may attenuate the frequency of the scratching through changing amino acid metabolism in the brain.
Keywords: Compound 48/80; Scratching; Amino acid; Monoamine.
Letters in Drug Design & Discovery
Title:L-DOPA Suppressed Scratching Behavior and Modified Brain Monoamine/ Amino Acid Concentrations in Mice
Volume: 10 Issue: 3
Author(s): Yoriko Akimoto, Shinobu Yasuo and Mitsuhiro Furuse
Affiliation:
Keywords: Compound 48/80; Scratching; Amino acid; Monoamine.
Abstract: The effects of L-DOPA (0, 25, and 50 mg/kg body weight) administration on peripheral pruritogen-induced scratching behavior and on brain monoamine and amino acid metabolism were investigated in mice. Intraperitoneal injection of L-DOPA significantly suppressed the number of scratches caused by subcutaneous injection of compound 48/80 (C48/80) in a dose-dependent manner. In the brain stem, C48/80 increased the norepinephrine turnover rate, but the change in the frequency of scratching was not paralleled by the changes in monoamine levels or by the monoamine turnover rates in the brain. On the other hand, most amino acids in the brain stem showed the highest levels in mice treated with C48/80 without L-DOPA, and these values were clearly decreased by L-DOPA administration. These changes in the concentrations of amino acids may be involved in the regulation of the frequency of scratching induced by L-DOPA. In particular, treatment with L-DOPA and C48/80 markedly decreased the concentrations of GABA, L-glutamine, Lglutamic acid, and glycine in the brain stem. In conclusion, L-DOPA administration may attenuate the frequency of the scratching through changing amino acid metabolism in the brain.
Export Options
About this article
Cite this article as:
Akimoto Yoriko, Yasuo Shinobu and Furuse Mitsuhiro, L-DOPA Suppressed Scratching Behavior and Modified Brain Monoamine/ Amino Acid Concentrations in Mice, Letters in Drug Design & Discovery 2013; 10 (3) . https://dx.doi.org/10.2174/1570180811310030002
DOI https://dx.doi.org/10.2174/1570180811310030002 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Relationships Between White Matter Hyperintensities, Cerebral Amyloid Angiopathy and Dementia in a Population-based Sample of the Oldest Old
Current Alzheimer Research Commentary: Olfactory Dysfunction in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets The Influence of Metabolism on the MAO-B Inhibitory Potency of Selegiline
Current Medicinal Chemistry Screening of Some Novel 4, 5 Disubstituted 1, 2, 4-Triazole-3-thiones for Anticonvulsant Activity
Central Nervous System Agents in Medicinal Chemistry Schistosoma mansoni Antigens as Modulators of the Allergic Inflammatory Response in Asthma
Endocrine, Metabolic & Immune Disorders - Drug Targets Mitochondrial Dysfunction in the Pathophysiology of Bipolar Disorder: Effects of Pharmacotherapy
Mini-Reviews in Medicinal Chemistry Psycho-Cognitive Intervention for ASD from Cross-Species Behavioral Analyses of Infants, Chicks and Common Marmosets
CNS & Neurological Disorders - Drug Targets Psychological and Mental Health Issues During the SARS-CoV-2 Global Pandemic: A Critical Analysis
Coronaviruses Two -Year Efficacy and Safety of Botulinum a Toxin Intravesical Injections in Patients Affected by Refractory Painful Bladder Syndrome
Current Drug Delivery Hemichannels in the Neurovascular Unit and White Matter Under Normal and Inflamed Conditions
CNS & Neurological Disorders - Drug Targets Immuno-Modulatory Properties of a Quinolin-2-(1H)-on-3-Carboxamide Derivative: Relevance in Multiple Sclerosis
Recent Patents on CNS Drug Discovery (Discontinued) Targeting Functional Biomarkers in Schizophrenia with Neuroimaging
Current Pharmaceutical Design A Hypothesis for Regenerative Therapy for Neuronal Disease: Stem Cells within Artificial Niche
Current Signal Transduction Therapy Magnesium as a Neuroprotective Agent in Cerebral Ischemia
Current Medicinal Chemistry - Central Nervous System Agents Antiplatelet Therapies: Platelet GPIIb / IIIa Antagonists and Beyond
Current Pharmaceutical Design S100A9 Exacerbates the Aβ1-42-mediated Innate Immunity in Human THP-1 Monocytes
CNS & Neurological Disorders - Drug Targets Editorial [Hot Topic: Drug Discovery for CNS Disorders: From Bench to Bedside (Guest Editor: Tiago Fleming Outeiro)]
CNS & Neurological Disorders - Drug Targets Investigation of Gene Expression Pattern of 5HTR2a and MAO-A in PBMCs of Individuals Who Had Been Exposed to Air Pollution in Highly Polluted Area
Recent Patents on Inflammation & Allergy Drug Discovery Non-Steroidal LXR Agonists; An Emerging Therapeutic Strategy for the Treatment of Atherosclerosis
Recent Patents on Cardiovascular Drug Discovery Major Depressive Disorder and Diabetes: Does Serotonin Bridge the Gap?
Current Diabetes Reviews